Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population.
Ulka N. Vaishampayan(University of Michigan), Amy Weise(Henry Ford Hospital), Hirva Mamdani(Wayne State University), Danielle Harfoot(The Barbara Ann Karmanos Cancer Institute), Lisa De Lange(The Barbara Ann Karmanos Cancer Institute), Andrea L. Jamison(The Barbara Ann Karmanos Cancer Institute), Seongho Kim(Wayne State University), Kelley Wilson(The Barbara Ann Karmanos Cancer Institute), Lindsay Williams(The Barbara Ann Karmanos Cancer Institute), Jaswinder Karwa(The Barbara Ann Karmanos Cancer Institute)
Cited by 0
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
|Journal of Clinical Oncology|2019|147
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125